Safety And Insurance Premium Implications For Hospitals Based On Subcutaneous Versus Intravenous Administration Of Oncology / Hematology Therapies- Case Studies With Rituximab (Mabthera) And Trastuzumab (Herceptin)
Nov 1, 2015, 00:00 AM
10.1016/j.jval.2015.09.1075
https://www.valueinhealthjournal.com/article/S1098-3015(15)03151-4/fulltext
Section Title :
Research Podium Presentations - Session 1 and Session 2
Section Order :
579
First Page :
A440
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03151-4&doi=10.1016/j.jval.2015.09.1075